A Phase 2/3 interventional study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH), sponsored by Electra Therapeutics Inc.. Recruiting at 42 sites in 7 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Electra Therapeutics Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States — 11 open to participants now, 19 under way, 1 of them phase 3. Lymphohistiocytosis, Hemophagocytic · United States.
Among the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States, this one has the largest planned enrollment of the 32 interventional ones that give a count, is the only one that started in 2022, is one of 5 in phase 2/3, reaches primary completion later than 10 of the 18 other live ones, and was the 35th registered.
111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.
Browse Lymphohistiocytosis, Hemophagocytic studies →11 of the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States are open now. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18–99
Jerry Lee, MD, MSc, MPhil · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–120
University of Alabama at Birmingham · Sites in United States
Children's Hospital Medical Center, Cincinnati · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 23 · Phase 3 6
First in 2000; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 156 is above the median of 30 across 75 interventional studies indexed under Lymphohistiocytosis, Hemophagocytic.
Median enrollment 21 across the 32 interventional studies, 200 across the 9 observational. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 42 have an industry lead sponsor. The 10 most frequent:
Electra Therapeutics Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Electra Therapeutics Inc. has 1 study filed under Lymphohistiocytosis, Hemophagocytic — fewer than ten, so there is no comparison to draw.
3 of the studies in Lymphohistiocytosis, Hemophagocytic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT03827343National Cancer Institute (NCI)Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer | 2026-12-31 |
| NCT05277272Children's Hospital Medical Center, CincinnatiINTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH) | 2027-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (eg, malignancy associated HLH (mHLH), infection, or autoimmune disease). ELA026 is a fully human immunoglobulin G1 (IgG1) signal regulatory protein (SIRP)-directed monoclonal antibody designed to deplete the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, efficacy pharmacokinetics and pharmacodynamics of ELA026 in participants with sHLH.
This study consists of two parts: Phase 1b (Part 1) and Phase 2/3 (Part 2).
Part 1 is designed to evaluate the safety, efficacy, pharmacodynamics, and pharmacokinetics of ELA026 in pediatric and adult participants with treatment-naïve (TN) and relapsed/refractory sHLH. The main objectives of Part 1 are to determine the safety of ELA026 administered intravenously (IV) and subcutaneously (SC) to participants with sHLH and to identify the recommended Phase 3 dose and schedule for ELA026. Participants will be enrolled into a dose-escalating cohort (Cohort 1) followed by two fixed dose cohorts (Cohorts 2-3) treated over 12-weeks.
Part 2 (SURPASS) is designed as an open-label, single-arm, multicenter, historical control registrational study to evaluate ELA026 in newly diagnosed TN adult and pediatric sHLH participants. All participants are diagnosed with HLH-2004 criteria unless indicated. Cohort A (primary cohort) will enroll newly diagnosed TN participants ≥18 years old with mHLH. Cohort B (exploratory cohort) will enroll participants including ≥18 years old participants with TN sHLH not triggered by malignancy; ≥18 years old participants with newly diagnosed TN mHLH diagnosed by biomarker criteria but not meeting HLH-2004 diagnostic criteria; and 6 to 17 year old participants with newly diagnosed TN sHLH (due to any trigger). For 6 to 12 year old participants, there is a safety lead-in cohort with refractory sHLH.
Part 1 is closed to recruitment and Part 2 is recruiting for eligible participants.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Key Inclusion Criteria for Part 1:
Key Inclusion Criteria for Part 2:
Key Exclusion Criteria for Part 1:
Key Exclusion Criteria for Part 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1: Single dose escalation up to 3.0 mg/kg IV or SC. Cohort 2: priming dose: 0.1 mg/kg IV on Day 1; 0.3 mg/kg IV on Day 2 - 4, followed by weekly maintenance doses of 1 mg/kg IV/SC from Day 8 to Day 81. Cohort 3: priming dose: 0.1 mg/kg IV on Day 1; 0.3 mg/kg IV on Days 2 - 4, followed by twice weekly maintenance doses of 0.5 mg/kg IV/SC from Day 8 to Day 81.
Drug: ELA026
Cohort A and Cohort B: priming dose: 0.1 mg/kg IV/SC on Day 1; loading dose 0.3 mg/kg IV/SC on Days 2 - 4, followed by twice weekly maintenance doses of 0.5 mg/kg (IV/SC) from Day 8 to Day 81.
Drug: ELA026
Multiple doses of ELA026
Part 1: Number of Participant with Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and tolerability]
Incidence of adverse events (AEs) including dose-limiting toxicities (DLTs), serious adverse events (SAEs), deaths, AEs leading to withdrawal from study
Time frame: Up to Week 12
Part 2 (Cohort A): 56-day Survival Rate in Participants with mHLH and Have Lymphoma as the Cancer Trigger
Time frame: 56 days
Number of Participants Achieving Early Survival (Cohort A)
Time frame: up to 90 days
Number of Participants Achieving HLH Disease Response by Day 29 (Cohort A)
HLH disease response includes achievement of CR, mCR, PR, or HI.
Time frame: Up to Day 29
Number of Participants with TEAEs (Cohort A)
Time frame: Up to Week 12
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Mar 2028, 70 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jun 2027 → Mar 2028 and completion Jun 2029 → Mar 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ipsoprubart
Lymphohistiocytosis, Hemophagocytic →
Electra Therapeutics Inc.